CoChat

Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma

Open access

Published version of a preprint

The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index; 26 of the 67 sources its claims cite were checked for support.

Abstract

Multiple clinical trials targeting the gut microbiome are being conducted to optimize treatment outcomes for immune checkpoint blockade (ICB). To improve the success of these interventions, understanding gut microbiome changes during ICB is urgently needed. Here through longitudinal microbiome profiling of 175 patients treated with ICB for advanced melanoma, we show that several microbial species-level genome bins (SGBs) and pathways exhibit distinct patterns from baseline in patients achieving progression-free survival (PFS) of 12 months or longer (PFS ≥12) versus patients with PFS shorter than 12 months (PFS <12). Out of 99 SGBs that could discriminate between these two groups, 20 were differentially abundant only at baseline, while 42 were differentially abundant only after treatment initiation. We identify five and four SGBs that had consistently higher abundances in patients with PFS ≥12 and <12 months, respectively. Constructing a log ratio of these SGBs, we find an association with overall survival. Finally, we find different microbial dynamics in different clinical contexts including the type of ICB regimen, development of immune-related adverse events and concomitant medication use. Insights into the longitudinal dynamics of the gut microbiome in association with host factors and treatment regimens will be critical for guiding rational microbiome-targeted therapies aimed at enhancing ICB efficacy.

Overview

CoChat Summary

TL;DR

Longitudinal shotgun metagenomic profiling of 175 patients with advanced melanoma receiving immune checkpoint blockade identified microbial species and pathways whose trajectories differ between patients with PFS ≥12 versus <12 months. A baseline balance of consistently higher taxa predicted PFS12 and overall survival, while microbial dynamics varied by ICB regimen, colitis and PPI use.

Key findings

  • Among 99 SGBs discriminating PFS ≥12 from PFS <12 months at ≥1 visit, 20 differed only at baseline, 42 only after treatment initiation, and 5 versus 4 SGBs remained consistently higher in PFS ≥12 and PFS <12 months, respectively.
  • A balance of the 5 PFS ≥12-associated and 4 PFS <12-associated SGBs discriminated PFS12 at T0–T2 (two-sided Wilcoxon P = 0.00085, 0.0007, 0.0005; T3 P = 0.1) with AUCs of 0.659 ± 0.092, 0.666 ± 0.091, 0.739 ± 0.118 and 0.655 ± 0.129; above-median patients had longer OS (35.4 versus 28.4 months; HR 1.669, P = 0.035).
  • Clinical context altered dynamics: 28 associations were shared between monotherapy and combination therapy, with 6 SGBs showing opposite patterns; a colitis-associated balance predicted colitis at baseline (P = 0.00055; AUC 0.723 ± 0.121), and PPI users on monotherapy shared 33 associations with nonusers.
  • Patients with PFS ≥12 months showed higher SCFA-related pathways and a polyamine synthesis pathway after baseline, whereas patients with PFS <12 months showed higher menaquinol synthesis pathways at baseline and early treatment.

Methods

  • Multicenter cohort of 175 patients with unresectable stage 3/4 cutaneous melanoma from five cohorts in the Netherlands, UK and Spain; 117 (67%) received anti-PD-1 monotherapy and 58 (33%) anti-PD-1/CTLA-4 combination therapy. Fecal shotgun metagenomics was performed at baseline and three subsequent visits over 12 weeks, yielding 408 samples from 175 patients after filtering.
  • Taxonomic and functional profiling used MetaPhlAn4 and MetaCyc; a Bayesian multinomial logistic normal regression model (Pibble/fido) with higher-order interactions modeled linear microbial trajectories by PFS ≥12 versus <12 months and clinical moderators (monotherapy versus combination, colitis, PPI use), adjusting for confounders; post hoc contrasts used 90% Bayesian confidence level.
  • Balances were computed as log ratios between selected SGB sets; associations with OS/PFS used Cox proportional hazards and Kaplan–Meier analysis, and the main balance was tested in six independent melanoma cohorts.

Limitations

  • Stated by the paper: microbial dynamics were simplified to linear trajectories; comparability with previous studies using different taxonomic databases is limited; and smaller patient numbers for some post hoc comparisons limit generalizability.
  • Evident from the text: the study is observational and does not establish causality; validation in independent cohorts was constrained by small sample sizes and heterogeneity, with only one reasonably large cohort (N = 112) showing discrimination for PFS12 and one small cohort (N = 27) predicting OS.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41591-024-02803-3

Cites

0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 High-level view of gut microbiome dynamics in patients with PFS ≥12 and PFS <12 months. a, For each microbial SGB listed, slopes are shown (that is, whether it is increasing or decreasing over study visits) in patients with PFS ≥12 (n = 83) and PFS <12 months (n = 92), respectively. For increased readability, SGBs differentially abundant in only one study visit have been removed (see Extended Data Fig. 2 for all SGBs). Red and blue colors indicate whether the focal SGB is increasing or decreasing in its abundance over study visits, respectively, with the strength of the colors corresponding to the steepness of the slope, with darker shades indicating steeper increases/decreases. It then shows, in the teal–brown heatmap, the average difference between the two slopes (that is, between patients with PFS ≥12 and PFS <12 months) across the different study visits. Non-gray cells in the heatmap correspond to the focal SGB’s log fold change in abundance between patients with PFS ≥12 and PFS <12 months, respectively. Teal cells correspond to study visits for which the abundance of the focal SGB is higher in patients with PFS ≥12 than with PFS <12 months, and vice versa for brown cells (at 90% BCL). Gray cells denote differences between patients with PFS ≥12 and PFS <12 months whose 90% credible interval cover zero. b, Three example features and how they increase and/or decrease in their expected abundance (represented in centered log ratio coordinates) over the study visits in patients with PFS ≥12 months (yellow slope) and in patients with PFS <12 months (purple slope). For each microbial SGB or pathway, the inset figure then displays the average difference between the two slopes at each study visit, including its 90% credible interval. These averages are the same as depicted in the teal–brown heatmap in a, and significance is deemed by evaluating whether or not the 90% credible interval covers zero. c, Microbial pathways are shown, similar to the format in a. The number (n) represents the number of patient samples at each visit for patients with PFS ≥12 and PFS <12 months.
Fig. 1 High-level view of gut microbiome dynamics in patients with PFS ≥12 and PFS <12 months. a, For each microbial SGB listed, slopes are shown (that is, whether it is increasing or decreasing over study visits) in patients with PFS ≥12 (n = 83) and PFS <12 months (n = 92), respectively. For increased readability, SGBs differentially abundant in only one study visit have been removed (see Extended Data Fig. 2 for all SGBs). Red and blue colors indicate whether the focal SGB is increasing or decreasing in its abundance over study visits, respectively, with the strength of the colors corresponding to the steepness of the slope, with darker shades indicating steeper increases/decreases. It then shows, in the teal–brown heatmap, the average difference between the two slopes (that is, between patients with PFS ≥12 and PFS <12 months) across the different study visits. Non-gray cells in the heatmap correspond to the focal SGB’s log fold change in abundance between patients with PFS ≥12 and PFS <12 months, respectively. Teal cells correspond to study visits for which the abundance of the focal SGB is higher in patients with PFS ≥12 than with PFS <12 months, and vice versa for brown cells (at 90% BCL). Gray cells denote differences between patients with PFS ≥12 and PFS <12 months whose 90% credible interval cover zero. b, Three example features and how they increase and/or decrease in their expected abundance (represented in centered log ratio coordinates) over the study visits in patients with PFS ≥12 months (yellow slope) and in patients with PFS <12 months (purple slope). For each microbial SGB or pathway, the inset figure then displays the average difference between the two slopes at each study visit, including its 90% credible interval. These averages are the same as depicted in the teal–brown heatmap in a, and significance is deemed by evaluating whether or not the 90% credible interval covers zero. c, Microbial pathways are shown, similar to the format in a. The number (n) represents the number of patient samples at each visit for patients with PFS ≥12 and PFS <12 months.CC BY · PubMed Central
Fig. 2 A longitudinal balance of microbial taxa (SGBs) predicts OS at baseline. a, Schematic illustration of a balance between the five SGBs that were consistently higher in patients with PFS ≥12 months (A. butyriciproducens SGB14993 group, I. bartlettii SGB6140, Dorea sp. AF24 7LB SGB4571, L. gasseri SGB7038 group and L. celerecrescens SGB4868) and the four SGBs that were found to be consistently higher in patients with PFS <12 months (R. lactatiformans SGB15271, R. unclassified SGB15265 group, P. copri clade A SGB1626 and an unidentified SGB from the phylum Bacteroidetes SGB1957). In patients with PFS ≥12 and PFS <12 months, the balance is tilted to the left and right side, respectively. b, The balance’s ability to discriminate between patients with PFS ≥12 (n = 83, n0 = 62, n1 = 77, n2 = 38 and n3 = 30) and PFS <12 months (n = 92, n0 = 74, n1 = 69, n2 = 34 and n3 = 24) months across study visits (two-sided Wilcoxon test: PT0 = 0.00085, PT1 = 0.0007, PT2 = 0.0005 and PT3 = 0.1). Boxplots represent minima, Q1, Q2, Q3 and maxima. c, The balance’s predictive ability expressed as the AUC computed from 100 times repeated five-fold cross-validation. Each line shows, for each study visit, the average across the 100 times repeated five-fold cross-validations with the shaded area representing the 95% CI (mean AUC ± s.d.: AUCT0 0.659 ± 0.092, AUCT1 0.666 ± 0.091, AUCT2 = 0.739 ± 0.118 and AUCT3 0.655 ± 0.129). The dashed diagonal line represents random chance. d, Kaplan–Meier curves and multivariable Cox regression of OS in months for 146 patients at baseline according to high (above median; teal) and low (below median; orange) values of the balance after adjusting for age, sex, BMI, previous therapy, PPI and antibiotics use.
Fig. 2 A longitudinal balance of microbial taxa (SGBs) predicts OS at baseline. a, Schematic illustration of a balance between the five SGBs that were consistently higher in patients with PFS ≥12 months (A. butyriciproducens SGB14993 group, I. bartlettii SGB6140, Dorea sp. AF24 7LB SGB4571, L. gasseri SGB7038 group and L. celerecrescens SGB4868) and the four SGBs that were found to be consistently higher in patients with PFS <12 months (R. lactatiformans SGB15271, R. unclassified SGB15265 group, P. copri clade A SGB1626 and an unidentified SGB from the phylum Bacteroidetes SGB1957). In patients with PFS ≥12 and PFS <12 months, the balance is tilted to the left and right side, respectively. b, The balance’s ability to discriminate between patients with PFS ≥12 (n = 83, n0 = 62, n1 = 77, n2 = 38 and n3 = 30) and PFS <12 months (n = 92, n0 = 74, n1 = 69, n2 = 34 and n3 = 24) months across study visits (two-sided Wilcoxon test: PT0 = 0.00085, PT1 = 0.0007, PT2 = 0.0005 and PT3 = 0.1). Boxplots represent minima, Q1, Q2, Q3 and maxima. c, The balance’s predictive ability expressed as the AUC computed from 100 times repeated five-fold cross-validation. Each line shows, for each study visit, the average across the 100 times repeated five-fold cross-validations with the shaded area representing the 95% CI (mean AUC ± s.d.: AUCT0 0.659 ± 0.092, AUCT1 0.666 ± 0.091, AUCT2 = 0.739 ± 0.118 and AUCT3 0.655 ± 0.129). The dashed diagonal line represents random chance. d, Kaplan–Meier curves and multivariable Cox regression of OS in months for 146 patients at baseline according to high (above median; teal) and low (below median; orange) values of the balance after adjusting for age, sex, BMI, previous therapy, PPI and antibiotics use.CC BY · PubMed Central
Fig. 3 Different taxon dynamics in patients with PFS ≥12 and PFS <12 months. a–d, Four different dynamics exemplified by different microbial SGBs with different dynamics in patients with PFS ≥12 (n0 = 62, n1 = 77, n2 = 38 and n3 = 30) and PFS <12 (n0 = 74, n1 = 69, n2 = 34 and n3 = 24) months, where the slopes of patients with PFS ≥12 months (yellow slopes) and patients with PFS <12 months (purple slopes) diverge from similar baseline abundances (a, dynamics 2a, Extended Data Fig. 7a), where the slopes of patients with PFS ≥12 and PFS <12 months are crossing (b, generating opposite abundance patterns when comparing baseline to the last study visit, dynamics 3b, Extended Data Fig. 7b), where the slope of the patients with PFS <12 months is relatively unchanged across the study visits compared to the slope of the patients with patients with PFS ≥12 months (c, dynamics 1c, Extended Data Fig. 7c); where the slope of the patients with PFS ≥12 months is relatively unchanged across the study visits compared to the slope of the patients with PFS <12 months (d, dynamics 2c, Extended Data Fig. 7c). The y axis shows the expected abundance (represented in centered log ratio coordinates) for each study visit (x axis). The corresponding inset figures show the average difference between patients with PFS ≥12 and PFS <12 months at each study visit, including its 90% credible interval. The number (n) represents the number of patient samples at each visit for patients with PFS ≥12 and PFS <12 months.
Fig. 3 Different taxon dynamics in patients with PFS ≥12 and PFS <12 months. a–d, Four different dynamics exemplified by different microbial SGBs with different dynamics in patients with PFS ≥12 (n0 = 62, n1 = 77, n2 = 38 and n3 = 30) and PFS <12 (n0 = 74, n1 = 69, n2 = 34 and n3 = 24) months, where the slopes of patients with PFS ≥12 months (yellow slopes) and patients with PFS <12 months (purple slopes) diverge from similar baseline abundances (a, dynamics 2a, Extended Data Fig. 7a), where the slopes of patients with PFS ≥12 and PFS <12 months are crossing (b, generating opposite abundance patterns when comparing baseline to the last study visit, dynamics 3b, Extended Data Fig. 7b), where the slope of the patients with PFS <12 months is relatively unchanged across the study visits compared to the slope of the patients with patients with PFS ≥12 months (c, dynamics 1c, Extended Data Fig. 7c); where the slope of the patients with PFS ≥12 months is relatively unchanged across the study visits compared to the slope of the patients with PFS <12 months (d, dynamics 2c, Extended Data Fig. 7c). The y axis shows the expected abundance (represented in centered log ratio coordinates) for each study visit (x axis). The corresponding inset figures show the average difference between patients with PFS ≥12 and PFS <12 months at each study visit, including its 90% credible interval. The number (n) represents the number of patient samples at each visit for patients with PFS ≥12 and PFS <12 months.CC BY · PubMed Central
Fig. 4 Divergent signals in monotherapy versus combination therapy. a–c, Three examples out of the six SGBs that exhibited divergent patterns in monotherapy (PFS ≥12: n0 = 41, n1 = 49, n2 = 29 and n3 = 25; PFS <12: n0 = 49, n1 = 48, n2 = 25 and n3 = 18) compared to combination therapy (PFS ≥12: n0 = 21, n1 = 28, n2 = 9 and n3 = 5; PFS <12: n0 = 25, n1 = 21, n2 = 9 and n3 = 6): C. eutactus (SGB5121) (a), Butyricicoccus sp. AM29 23AC (SGB14991) (b) and P. merdae (SGB1949) (c). The y axis shows the expected abundance (represented in centered log ratio coordinates) for each study visit (x axis). Left: anti-PD-1 monotherapy. Right: anti-PD-1/anti-CTLA-4 combination therapy. The corresponding inset figures show the average difference between patients with PFS ≥12 and PFS <12 months at each study visit, including its 90% credible interval. The number (n) represents the number of patient samples at each visit for patients with PFS ≥12 and PFS <12 months.
Fig. 4 Divergent signals in monotherapy versus combination therapy. a–c, Three examples out of the six SGBs that exhibited divergent patterns in monotherapy (PFS ≥12: n0 = 41, n1 = 49, n2 = 29 and n3 = 25; PFS <12: n0 = 49, n1 = 48, n2 = 25 and n3 = 18) compared to combination therapy (PFS ≥12: n0 = 21, n1 = 28, n2 = 9 and n3 = 5; PFS <12: n0 = 25, n1 = 21, n2 = 9 and n3 = 6): C. eutactus (SGB5121) (a), Butyricicoccus sp. AM29 23AC (SGB14991) (b) and P. merdae (SGB1949) (c). The y axis shows the expected abundance (represented in centered log ratio coordinates) for each study visit (x axis). Left: anti-PD-1 monotherapy. Right: anti-PD-1/anti-CTLA-4 combination therapy. The corresponding inset figures show the average difference between patients with PFS ≥12 and PFS <12 months at each study visit, including its 90% credible interval. The number (n) represents the number of patient samples at each visit for patients with PFS ≥12 and PFS <12 months.CC BY · PubMed Central
Fig. 5 A balance predictive of ICB-induced colitis at baseline. A balance between the 10 SGBs associated with the presence of colitis (red; n = 24 patients) and the 12 SGBs associated with the absence of colitis (blue; n = 112 patients) at baseline is predictive of colitis development at baseline. Left: the balance’s discriminatory ability (two-sided Wilcoxon test, PT0 = 0.00055). Boxplots represent minima, Q1, Q2, Q3 and maxima. Right: the same balance’s predictive ability expressed as the averaged AUC computed from a 100 times repeated five-fold cross-validation (AUC mean ± s.d. of 0.723 ± 0.121). The dashed diagonal line represents random chance.
Fig. 5 A balance predictive of ICB-induced colitis at baseline. A balance between the 10 SGBs associated with the presence of colitis (red; n = 24 patients) and the 12 SGBs associated with the absence of colitis (blue; n = 112 patients) at baseline is predictive of colitis development at baseline. Left: the balance’s discriminatory ability (two-sided Wilcoxon test, PT0 = 0.00055). Boxplots represent minima, Q1, Q2, Q3 and maxima. Right: the same balance’s predictive ability expressed as the averaged AUC computed from a 100 times repeated five-fold cross-validation (AUC mean ± s.d. of 0.723 ± 0.121). The dashed diagonal line represents random chance.CC BY · PubMed Central
Extended Data Fig. 1 Study description with sample numbers across study visits. Samples were collected within 5 sub-cohorts: two prospectively recruited within parallel observational studies (The PRIMM cohorts), and three retrospectively pooled cohorts. Fecal samples were collected at 4 timepoints: at baseline (T0) and at every treatment cycle (T1 to T3) over a period of 12 weeks. The time between two samples was 3 or 4 weeks, depending on the treatment regimen, with Ipilimumab/Nivolumab combination therapy and Pembrolizumab monotherapy administered 3-weekly and Nivolumab monotherapy administered 4-weekly. Treatment continued after the 12 weeks until the patient responded or until the treatment had to pause/stop due to irAEs. Not all subjects provided fecal samples at all study visits. Therefore, gut microbial dynamics were modeled at the level of the population including a random effect for the patient identifier (see Methods). Sample numbers represent patients with complete metadata (that is, no missingness) for all considered covariates/confounders. For the survival analysis, because we adjusted for a smaller number of covariates/confounders, there were n = 147 at baseline (PRIMM-UK = 41; PRIMM-NL = 53; Barcelona = 12; Leeds = 17; Manchester = 24) rather than n = 136 as indicated here. Tumor staging by CT or PET-scans was performed at study entry and at regular intervals during treatment. Tumor response was classified using the Response Evaluation Criteria in Solid Tumors (RECIST) v.1. Endpoints were defined as Progression-free survival at 12 months (PFS12) and overall survival (OS). Immune-related adverse events (irAEs) were assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v.5 (see Table 1). ICB, Immune checkpoint blockade; PRIMM, Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and Metabolomics; NL, Netherland; UK, United Kingdom. The figure was generated in BioRender.com.
Extended Data Fig. 1 Study description with sample numbers across study visits. Samples were collected within 5 sub-cohorts: two prospectively recruited within parallel observational studies (The PRIMM cohorts), and three retrospectively pooled cohorts. Fecal samples were collected at 4 timepoints: at baseline (T0) and at every treatment cycle (T1 to T3) over a period of 12 weeks. The time between two samples was 3 or 4 weeks, depending on the treatment regimen, with Ipilimumab/Nivolumab combination therapy and Pembrolizumab monotherapy administered 3-weekly and Nivolumab monotherapy administered 4-weekly. Treatment continued after the 12 weeks until the patient responded or until the treatment had to pause/stop due to irAEs. Not all subjects provided fecal samples at all study visits. Therefore, gut microbial dynamics were modeled at the level of the population including a random effect for the patient identifier (see Methods). Sample numbers represent patients with complete metadata (that is, no missingness) for all considered covariates/confounders. For the survival analysis, because we adjusted for a smaller number of covariates/confounders, there were n = 147 at baseline (PRIMM-UK = 41; PRIMM-NL = 53; Barcelona = 12; Leeds = 17; Manchester = 24) rather than n = 136 as indicated here. Tumor staging by CT or PET-scans was performed at study entry and at regular intervals during treatment. Tumor response was classified using the Response Evaluation Criteria in Solid Tumors (RECIST) v.1. Endpoints were defined as Progression-free survival at 12 months (PFS12) and overall survival (OS). Immune-related adverse events (irAEs) were assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v.5 (see Table 1). ICB, Immune checkpoint blockade; PRIMM, Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and Metabolomics; NL, Netherland; UK, United Kingdom. The figure was generated in BioRender.com.CC BY · PubMed Central
Extended Data Fig. 2 Extension of Fig. 1. This includes all SGBs, that is, also those that were differentially abundant in only one study visit.
Extended Data Fig. 2 Extension of Fig. 1. This includes all SGBs, that is, also those that were differentially abundant in only one study visit.CC BY · PubMed Central
Extended Data Fig. 3 Extended longitudinal balance. The extended balance has 12 SGBs in the numerator (A. butyriciproducens [SGB14993 group], I. bartlettii [SGB6140], D. sp AF24 7LB [SGB4571], L. gasseri [SGB7038 group], L. celerecrescens [SGB4868], R. sp NSJ 71 [SGB4290], GGB9640 [SGB15115], E. rectale [SGB4933 group], E. entriosum [SGB5045], E. sp AM28 29 [SGB6796 group], Clostridium sp AF15 49 [SGB5111], and A. bouchesdurhonensis [SGB17152]) and 9 SGBs in the denominator (R. lactatiformans [SGB15271], R. unclassified [SGB15265 group], P. copri clade A [SGB1626], GGB1420 [SGB1957], Gemmiger [SGB15299], B. obeum [SGB4809], Clostridiales unclassified [SGB15145], P. vulgatus [SGB1814], and B. clarus [SGB1832]). Panel (A) balance’s ability to discriminate between patients with PFS ≥ 12 (n = 83; n0 = 62; n1 = 77; n2 = 38; n3 = 30) and PFS < 12 (n = 92; n0 = 74; n1 = 69; n2 = 34; n3 = 24) months across study visits. Boxplots represent minima, Q1, Q2, Q3, and maxima. Panel (B) the balance’s predictive ability expressed as the Area Under the Curve (AUC) computed from 100 times repeated five-fold cross-validation (CV). Each line shows, for each study visit, the average across the 100 repeated five-fold CVs with the shaded area representing the 95% confidence interval. Panel (C) Kaplan–Meier curves and multivariable Cox regression analysis of overall survival in 146 patients at baseline (one patient was removed due to missingness in the included predictor variables) according to high (above median) and low (below median) values of the balance after adjusting for age, sex, BMI, previous therapy, PPI and antibiotic use.
Extended Data Fig. 3 Extended longitudinal balance. The extended balance has 12 SGBs in the numerator (A. butyriciproducens [SGB14993 group], I. bartlettii [SGB6140], D. sp AF24 7LB [SGB4571], L. gasseri [SGB7038 group], L. celerecrescens [SGB4868], R. sp NSJ 71 [SGB4290], GGB9640 [SGB15115], E. rectale [SGB4933 group], E. entriosum [SGB5045], E. sp AM28 29 [SGB6796 group], Clostridium sp AF15 49 [SGB5111], and A. bouchesdurhonensis [SGB17152]) and 9 SGBs in the denominator (R. lactatiformans [SGB15271], R. unclassified [SGB15265 group], P. copri clade A [SGB1626], GGB1420 [SGB1957], Gemmiger [SGB15299], B. obeum [SGB4809], Clostridiales unclassified [SGB15145], P. vulgatus [SGB1814], and B. clarus [SGB1832]). Panel (A) balance’s ability to discriminate between patients with PFS ≥ 12 (n = 83; n0 = 62; n1 = 77; n2 = 38; n3 = 30) and PFS < 12 (n = 92; n0 = 74; n1 = 69; n2 = 34; n3 = 24) months across study visits. Boxplots represent minima, Q1, Q2, Q3, and maxima. Panel (B) the balance’s predictive ability expressed as the Area Under the Curve (AUC) computed from 100 times repeated five-fold cross-validation (CV). Each line shows, for each study visit, the average across the 100 repeated five-fold CVs with the shaded area representing the 95% confidence interval. Panel (C) Kaplan–Meier curves and multivariable Cox regression analysis of overall survival in 146 patients at baseline (one patient was removed due to missingness in the included predictor variables) according to high (above median) and low (below median) values of the balance after adjusting for age, sex, BMI, previous therapy, PPI and antibiotic use.CC BY · PubMed Central
Extended Data Fig. 4 Treating balances as continuous independent variables. Panel A-C shows a multivariable Cox regression analysis of overall survival (OS) in months for 146 patients at baseline (one patient was removed due to missingness in the included predictor variables) treating (a) the first balance (Fig. 2a), (b) the second balance (that is, the extended longitudinal balance), and (c) the third balance (that is, the ‘baseline only’ balance) as a continuous independent variable. While the histograms show the distribution of each balance (right y-axes), each regression line represent the hazard ratio as a smooth function of each balance (left y-axes). All models are adjusted for age, sex, BMI, PPI and antibiotics use, and previous therapy.
Extended Data Fig. 4 Treating balances as continuous independent variables. Panel A-C shows a multivariable Cox regression analysis of overall survival (OS) in months for 146 patients at baseline (one patient was removed due to missingness in the included predictor variables) treating (a) the first balance (Fig. 2a), (b) the second balance (that is, the extended longitudinal balance), and (c) the third balance (that is, the ‘baseline only’ balance) as a continuous independent variable. While the histograms show the distribution of each balance (right y-axes), each regression line represent the hazard ratio as a smooth function of each balance (left y-axes). All models are adjusted for age, sex, BMI, PPI and antibiotics use, and previous therapy.CC BY · PubMed Central
Extended Data Fig. 5 Generalizability of the longitudinal balance (Fig. 2a) across six independent melanoma cohorts. Panel (A) shows the AUC for each independent baseline cohort, including the current study (in red). Panel (B) shows the AUC for McCullochJA_2022’s post-ICB cohort. Panel (C) shows the average difference in the balance score between patients with PFS < 12 months versus PFS ≥ 12 months from the SpencerCN_2021 cohort. Finally, panel (D) shows Kaplan-Meier curves and multivariable Cox regression analysis of overall survival (OS) in months from 27 patients from McCullochJA_2022’s baseline cohort according to high (≥75 percentile) and low (<75 percentile) values of the balance after adjusting for age, sex, BMI and PPI-use.
Extended Data Fig. 5 Generalizability of the longitudinal balance (Fig. 2a) across six independent melanoma cohorts. Panel (A) shows the AUC for each independent baseline cohort, including the current study (in red). Panel (B) shows the AUC for McCullochJA_2022’s post-ICB cohort. Panel (C) shows the average difference in the balance score between patients with PFS < 12 months versus PFS ≥ 12 months from the SpencerCN_2021 cohort. Finally, panel (D) shows Kaplan-Meier curves and multivariable Cox regression analysis of overall survival (OS) in months from 27 patients from McCullochJA_2022’s baseline cohort according to high (≥75 percentile) and low (<75 percentile) values of the balance after adjusting for age, sex, BMI and PPI-use.CC BY · PubMed Central
Extended Data Fig. 6 Baseline only balance. A ‘baseline only’ balance containing the 9 species associated with patients with PFS ≥ 12 months at baseline only in the numerator, and the 11 SGBs associated with patients with PFS < 12 months at baseline only in the denominator (see Fig. 1a). Kaplan-Meier curves and multivariable Cox regression analysis of overall survival in 146 patients at baseline (one patient was removed due to missingness in the included predictor variables) according to high (above median) and low (below median) values of the balance after adjusting for age, sex, BMI, previous therapy, PPI and antibiotic use.
Extended Data Fig. 6 Baseline only balance. A ‘baseline only’ balance containing the 9 species associated with patients with PFS ≥ 12 months at baseline only in the numerator, and the 11 SGBs associated with patients with PFS < 12 months at baseline only in the denominator (see Fig. 1a). Kaplan-Meier curves and multivariable Cox regression analysis of overall survival in 146 patients at baseline (one patient was removed due to missingness in the included predictor variables) according to high (above median) and low (below median) values of the balance after adjusting for age, sex, BMI, previous therapy, PPI and antibiotic use.CC BY · PubMed Central
Extended Data Fig. 7 Schematic illustration showing the different types of microbial dynamics we observe between patients with PFS ≥ 12 months and PFS < 12 months. Panels A-E are schematic illustrations (that is, cartoons) showing the breakdown of the different types of taxon dynamics we observe in the overall comparison between patients with PFS ≥ 12 months and patients with PFS < 12 months. Yellow and purple slopes correspond to patients with PFS ≥ 12 and PFS < 12 months, respectively. Panel (A) shows dynamics where patients with PFS ≥ 12 and PFS < 12 months are differentially abundant only after T0 (that is, dynamics 1a and 2a). Dynamics 3a is a particular case of dynamics 1a and 2a where the slopes for patients with PFS ≥ 12 and PFS < 12 months intersect. Panel (B) shows dynamics where patients with PFS ≥ 12 and PFS < 12 months are differentially abundant at early but not at late visits (that is, dynamics 1b and 2b). Dynamics 3b is a special case of dynamics 1b and 2b where the patients with PFS ≥ 12 and PFS < 12 months slopes intersect. Panel (C) shows dynamics where the slope of one of the groups is zero (or close to zero) while the other group is either increasing or decreasing, respectively (that is, dynamics 1c and 2c). In panels (D) and (E), included the inset figures, patients with PFS ≥ 12 and PFS < 12 months exhibit parallel lines (that is, no statistical interactions); Panel 1d and 2d shows dynamics where both patients with PFS ≥ 12 and PFS < 12 months are either increasing or decreasing, respectively, while in panels 1f and 2f, the slopes of patients with PFS ≥ 12 and PFS < 12 months are zero (or close to zero). The number in each plot corresponds to the number of microbial SGBs that follow each type of different dynamics.
Extended Data Fig. 7 Schematic illustration showing the different types of microbial dynamics we observe between patients with PFS ≥ 12 months and PFS < 12 months. Panels A-E are schematic illustrations (that is, cartoons) showing the breakdown of the different types of taxon dynamics we observe in the overall comparison between patients with PFS ≥ 12 months and patients with PFS < 12 months. Yellow and purple slopes correspond to patients with PFS ≥ 12 and PFS < 12 months, respectively. Panel (A) shows dynamics where patients with PFS ≥ 12 and PFS < 12 months are differentially abundant only after T0 (that is, dynamics 1a and 2a). Dynamics 3a is a particular case of dynamics 1a and 2a where the slopes for patients with PFS ≥ 12 and PFS < 12 months intersect. Panel (B) shows dynamics where patients with PFS ≥ 12 and PFS < 12 months are differentially abundant at early but not at late visits (that is, dynamics 1b and 2b). Dynamics 3b is a special case of dynamics 1b and 2b where the patients with PFS ≥ 12 and PFS < 12 months slopes intersect. Panel (C) shows dynamics where the slope of one of the groups is zero (or close to zero) while the other group is either increasing or decreasing, respectively (that is, dynamics 1c and 2c). In panels (D) and (E), included the inset figures, patients with PFS ≥ 12 and PFS < 12 months exhibit parallel lines (that is, no statistical interactions); Panel 1d and 2d shows dynamics where both patients with PFS ≥ 12 and PFS < 12 months are either increasing or decreasing, respectively, while in panels 1f and 2f, the slopes of patients with PFS ≥ 12 and PFS < 12 months are zero (or close to zero). The number in each plot corresponds to the number of microbial SGBs that follow each type of different dynamics.CC BY · PubMed Central
Extended Data Fig. 8 Patients with PFS ≥ 12 and PFS < 12 months on monotherapy. Panel (A) shows, for each microbial SGB listed, its slopes in patients with PFS ≥ 12 months and PFS < 12 months on monotherapy, respectively. Red and blue colors indicate whether the focal SGB is increasing or decreasing in its abundance over study visits, respectively. It then shows the average difference between patients with PFS ≥ 12 and PFS < 12 months across the different study visits. Non-gray cells in the heatmap correspond to the focal SGB’s log-fold change in abundance between patients with PFS ≥ 12 and PFS < 12 months, respectively. Teal cells correspond to study visits for which the abundance of the focal SGB is higher in in patients with PFS ≥ 12 than with PFS < 12 months on monotherapy, and vice versa for brown cells (at 90% BCL). Gray cells denote differences between patients with PFS ≥ 12 and PFS < 12 months on monotherapy whose 90% CI overlapped with zero.
Extended Data Fig. 8 Patients with PFS ≥ 12 and PFS < 12 months on monotherapy. Panel (A) shows, for each microbial SGB listed, its slopes in patients with PFS ≥ 12 months and PFS < 12 months on monotherapy, respectively. Red and blue colors indicate whether the focal SGB is increasing or decreasing in its abundance over study visits, respectively. It then shows the average difference between patients with PFS ≥ 12 and PFS < 12 months across the different study visits. Non-gray cells in the heatmap correspond to the focal SGB’s log-fold change in abundance between patients with PFS ≥ 12 and PFS < 12 months, respectively. Teal cells correspond to study visits for which the abundance of the focal SGB is higher in in patients with PFS ≥ 12 than with PFS < 12 months on monotherapy, and vice versa for brown cells (at 90% BCL). Gray cells denote differences between patients with PFS ≥ 12 and PFS < 12 months on monotherapy whose 90% CI overlapped with zero.CC BY · PubMed Central
Extended Data Fig. 9 Patients with PFS ≥ 12 and PFS < 12 months on combination therapy. Panel (A) shows, for each microbial SGB listed, its slopes in patients with PFS ≥ 12 months and PFS < 12 months on combination therapy, respectively. Red and blue colors indicate whether the focal SGB is increasing or decreasing in its abundance over study visits, respectively. It then shows the average difference between patients with PFS ≥ 12 and PFS < 12 months across the different study visits. Non-gray cells in the heatmap correspond to the focal SGB’s log-fold change in abundance between patients with PFS ≥ 12 and PFS < 12 months, respectively. Teal cells correspond to study visits for which the abundance of the focal SGB is higher in in patients with PFS ≥ 12 than with PFS < 12 months on combination therapy, and vice versa for brown cells (at 90% BCL). Gray cells denote differences between patients with PFS ≥ 12 and PFS < 12 months on combination therapy whose 90% CI overlapped with zero.
Extended Data Fig. 9 Patients with PFS ≥ 12 and PFS < 12 months on combination therapy. Panel (A) shows, for each microbial SGB listed, its slopes in patients with PFS ≥ 12 months and PFS < 12 months on combination therapy, respectively. Red and blue colors indicate whether the focal SGB is increasing or decreasing in its abundance over study visits, respectively. It then shows the average difference between patients with PFS ≥ 12 and PFS < 12 months across the different study visits. Non-gray cells in the heatmap correspond to the focal SGB’s log-fold change in abundance between patients with PFS ≥ 12 and PFS < 12 months, respectively. Teal cells correspond to study visits for which the abundance of the focal SGB is higher in in patients with PFS ≥ 12 than with PFS < 12 months on combination therapy, and vice versa for brown cells (at 90% BCL). Gray cells denote differences between patients with PFS ≥ 12 and PFS < 12 months on combination therapy whose 90% CI overlapped with zero.CC BY · PubMed Central
Extended Data Fig. 10 Patients who developed and not developed colitis. The figure shows, for each microbial SGB listed, its slopes in patients who developed and not developed colitis, respectively, regardless of response to therapy. Red and blue colors indicate whether the focal SGB is increasing or decreasing in its abundance over study visits, respectively. It then shows the average difference between patients with and without colitis across the different study visits. Non-gray cells in the heatmap correspond to the focal SGB’s log-fold change in abundance between patients with and without colitis, respectively. Teal cells correspond to study visits for which the abundance of the focal SGB is higher in in patients who developed colitis compared to those resistant to colitis, and vice versa for brown cells (at 90% BCL). Gray cells denote differences between patients with and without colitis whose 90% CI overlapped with zero.
Extended Data Fig. 10 Patients who developed and not developed colitis. The figure shows, for each microbial SGB listed, its slopes in patients who developed and not developed colitis, respectively, regardless of response to therapy. Red and blue colors indicate whether the focal SGB is increasing or decreasing in its abundance over study visits, respectively. It then shows the average difference between patients with and without colitis across the different study visits. Non-gray cells in the heatmap correspond to the focal SGB’s log-fold change in abundance between patients with and without colitis, respectively. Teal cells correspond to study visits for which the abundance of the focal SGB is higher in in patients who developed colitis compared to those resistant to colitis, and vice versa for brown cells (at 90% BCL). Gray cells denote differences between patients with and without colitis whose 90% CI overlapped with zero.CC BY · PubMed Central

Verification

Claims the paper makes

13 Valid · 1 Not valid · 18 Not checked · 99 Own results and interpretations

49 more claims

Create a free account to see all 131 claims and to verify the 41 references still open.

See all claims — free account
  • Probably not a substantial claim. 47
  • It may state two separate claims as one. 43

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 80 references

Cited by

See all 156

Metadata

Authors
Björk, J. R., Bolte, L. A., Maltez Thomas, A., Lee, K. A., Rossi, N., Wind, T. T., Smit, L. M., Armanini, F., Asnicar, F., Blanco-Miguez, A., Board, R., Calbet-Llopart, N., Derosa, L., Dhomen, N., Brooks, K., Harland, M., Harries, M., Lorigan, P., Manghi, P., Marais, R., Newton-Bishop, J., Nezi, L., Pinto, F., Potrony, M., Puig, S., Serra-Bellver, P., Shaw, H. M., Tamburini, S., Valpione, S., Waldron, L., Zitvogel, L., Zolfo, M., de Vries, E. G. E., Nathan, P., Fehrmann, R. S. N., Spector, T. D., Bataille, V., Segata, N., Hospers, G. A. P., & Weersma, R. K.
Affiliations
  • University Medical Center Groningen (NL)
  • King's College London (GB)
  • University of Trento (IT)
  • Inserm (FR)
  • University of Manchester (GB)
  • University of Leeds (GB)
  • Guy's Hospital (GB)
  • European Institute of Oncology (IT)
  • Instituto de Salud Carlos III (ES)
  • The Christie NHS Foundation Trust (GB)
  • Mount Vernon Cancer Centre (GB)
  • City University of New York (US)
Corresponding author
  • Björk, Johannes R.
  • Weersma, Rinse K.
Venue
Nature Medicine
Published
2024-02-16
Volume
30
Issue
3
Pages
785-796
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4391883183
Cited by
156
References
79
Citations by year
2026: 57 · 2025: 66 · 2024: 32
FWCI
21.04
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • HAL (submittedVersion, cc-by)
  • Iris (University of Trento) (submittedVersion, cc-by)
  • ARCA (Università Ca' Foscari Venezia) (submittedVersion, cc-by)
  • Research Explorer (The University of Manchester) (submittedVersion, cc-by)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
Funders
  • Amgen
  • Bristol-Myers Squibb
  • AstraZeneca
  • World Health Organization
  • Regeneron Pharmaceuticals
  • Wellcome Trust (100282/Z/12/Z)
  • Les Laboratories Pierre Fabre
  • Seerave Foundation
  • G1 Therapeutics
  • European Commission (825410)
  • Ministero dell’Istruzione, dell’Università e della Ricerca (RBFR13EWWI_001)
  • Università degli Studi di Trento
  • European Society for Medical Oncology
  • Institut Gustave-Roussy
  • NeraCare
  • National Institutes of Health (1u01ca230551-01a1, 1U01CA230551)
  • Genentech
  • Chugai Pharmaceutical
  • Medical Research Council (MR/MO19012/1)
  • Instituto de Salud Carlos III (PI15/00716, PI15/00956)
  • National Cancer Institute (1U01CA230551, U01 CA230551, R01CA230551)
  • Daiichi Sankyo Europe
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
Keywords
gut microbiota, immune checkpoint blockade, advanced melanoma, progression-free survival, overall survival, immune-related adverse events, microbiome-targeted therapy, immunotherapy response
MeSH terms
Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Cognition, Humans, Melanoma, Microbiota

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma. https://app.cochat.ai/papers/10.1038/s41591-024-02803-3
The paper
Björk, J. R., Bolte, L. A., Maltez Thomas, A., Lee, K. A., Rossi, N., Wind, T. T., Smit, L. M., Armanini, F., Asnicar, F., Blanco-Miguez, A., Board, R., Calbet-Llopart, N., Derosa, L., Dhomen, N., Brooks, K., Harland, M., Harries, M., Lorigan, P., Manghi, P., . . . Weersma, R. K. (2024). Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma. Nature Medicine. https://doi.org/10.1038/s41591-024-02803-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.